Twist Bioscience Corporation TWST Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Twist Bioscience Corporation in its filing.
Tagged under the XBRL concept us-gaap:RevenueRemainingPerformanceObligation.
The source filing: Twist Bioscience Corporation’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:28 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001581280-26-000040
In addition, for all periods presented, there was no revenue recognized in a reporting period from performance obligations satisfied in previous periods. The aggregate amount of the transaction price allocated to the performance obligations that are unsatisfied as of March 31, 2026 was $16.6 million. The Company expects to recognize revenue over the next twelve months relating to performance obligations unsatisfied as of March 31, 2026.
Item 1. Financial Statements (unaudited)
FAQ
- What is Twist Bioscience Corporation's deferred revenue?
- Twist Bioscience Corporation (TWST) reported deferred revenue of $16.6M in Q1 2026.
- How has Twist Bioscience Corporation's deferred revenue changed year-over-year?
- Twist Bioscience Corporation's deferred revenue increased by 95.3% year-over-year, from $8.5M to $16.6M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.
Ask your AI about Twist Bioscience Corporation's deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
